Bone replacement material Osbone® scores points in clinical multicenter study

18.10.2012 18:23

The advantages of the new synthetic hydroxyapatite Osbone® are particularly evident in indications that require increased mechanical stability. This is proven by a now published open, prospective, multicenter, clinical study on the use of the product in various areas of dental surgery.

32 dental and oral and maxillofacial surgery practices across Germany took part. 190 patients were treated and observed over a period of two years. A total of 458 locations were augmented and 400 implants were placed. The most common procedure in the study was sinus floor elevation.

On behalf of the numerous study participants, Dr. Andreas Holweg, Fulda, Henriette Lerner, Baden-Baden, and Dr. Kay Pehrsson, Herne, published the results as authors. These show that Osbone® offers advantages due to its specific properties and slow absorption kinetics, especially in indications that require increased mechanical stability.

The study results confirm that Osbone® has excellent biocompatibility and osseointegration. There were no complications related to the material. The available bone in the insertion area at the time of implantation was rated as optimal to good in 68% of the evaluated cases, the gingival conditions in 94%.

Osbone® granules consist of synthetically produced hydroxyapatite, which, due to its phase purity, ensures very good healing behavior and thus a stable defect filling.

The material is particularly distinguished from bone building materials of biological origin in that it can be produced with precisely definable properties. This means that it has a consistent batch quality, which enables a more predictable biological reaction.

Osbone® is extremely similar to human cancellous bone. Its interconnecting, open multi-porosity of around 80% and the polygonal granulate structure offer the organism the best possible conditions for rapid osseointegration and rapid vascularization with high stability.

Since Osbone® is manufactured synthetically, it has the advantage over materials of biological origin that possible complications of bone removal and transplantation as well as the problem of rejection reactions or potential allergy and residual infection risks do not have to be discussed during patient education, as is the case when using biological material.

Since the beginning of 2012, Osbone® has been sold globally in the dental market by Zimmer Dental Inc., Carlsbad, USA, under the brand IngeniOsTM HA.